Abstract:OBJECTIVE:To explore the clinical effect of L-ornithine L-aspartate (LOLA) granules in treating chronic liver disease in patients with high-level serum gamma-glutamyltransferase (G-GT) using a 24-week treatment course.METHODS:Two-hundred patients with chronic liver disease and above normal G-GT were given a 12-week course of LOLA granules (9 g/d) and then classified into the following three groups according to the change in serum Gamma-GT:group I:patients with Gamma-GT level returned to normal;group II:patients with serum Gamma-GT level that was reduced during the treatment; group III:patients with serum Gamma-GT level that did not decrease or that increased to a higher level than at start of treatment.After the 12-week treatment course, the patients in group I were divided into three subgroups for receipt of a control drug (compound glycyrrhizin, 50mg/d) or an additional 12-week course of Gamma-GT at a reduced dose (LOLA granules 3 g/d) or at the original dose; groups II and III were maintained on the initial dose for an additional 12 weeks.The groups were reassessed at the end of the second 12-week course (at the end of week 24 of the study's observation period).Count data were compared using the x2 test and measurement data were compared using the t-test.RESULTS:In group I, the serum Gamma-GT level was 90.9% at the end of the first 12-week course and dropped to a mean level of 52.2% for both of the subgroups that received the reduced and original dose after the additional 12 weeks of LOLA granules treatment; the difference from week 12 to week 24 was significant (x2=8.213, P less than 0.05).The 24-week change in serum Gamma-GT levels for the group I reduced and original dose subgroups vs.the control subgroup were also significantly different from those seen in groups II and III (P less than 0.05).The percentage of patients in group I who achieved normal level serum Gamma-GT after 24 weeks of treatment (78.6%) was significantly higher than that for the control group (vs.55.0%, x2=11.452, P less than 0.05).When the patients in group 1 who had received the 12 additional weeks of LOLA granules treatment were measured again at two weeks after the treatments had been discontinued (end of week 26), the percentage of patients with normal serum Gamma-GT level was 92.7%, with only three cases showing obviously abnormal levels; in contrast, the group I patients in the control group of the second 12-week study period had on 66.7% of patients with normal-level serum Gamma-GT.The difference in change between the treated groups (both reduced and original dose) and the control group was significant (x2=14.964, P less than 0.05).CONCLUSION:Patients whose serumGamma-GT levels returned to normal after receipt of LOLA granules for 12 weeks benefitted from an additional 12 weeks of consolidation treatment, and those given the treatment at the original dose benefitted most.Compared with the compound glycyrrhizin, LOLA granules provided a better maintenance of resolved Gamma-GT level.Therefore, the effect of LOLA appears to be reliable and stable as well as safe for clinical use.

Effect of intra-venous dipetide Ala-Gln on the severity of EN related diarrhea in aged patients

The Effect of Dipeptiven in Patients after Allogenic Hematologic Stem Cell Transplantation.

Effects of Enteral Nutrition Preparations on Glucose and Lipid Metabolism in Elderly Diabetic Patients

Effects of alanyl-glutamine dipeptide administration on postoperative intestinal permeability and systemic inflammatory response

Effects of alanyl-glutamine dipeptide administration on postoperative intestinal permeability and immmunologic function

Effect of Enteral Nutrition on T Lymphocytes-Mediated Immune Function in Patients with Acquired Immune Deficiency Syndrome

Effects of alanyl-glutamine dipeptide on postoperative intestinal permeability and stress response

Effects of early enteral nutrition and glutamine-supplemented EEN on the inflammatory response and immune function in patients with severe acute pancreatitis

Efficacy Analysis on Combination Use of Endoscopy and Enteral Nutrition in the Treatment of Acute Biliary Pancreatitis in Elderly Patients

Effect of alanyl-glutamine on nutrition and immune in patients with respiratory failure

Glucagon-Like Peptide-2 Modulates Enteric Paneth Cells Immune Response and Alleviates Gut Inflammation During Intravenous Fluid Infusion in Mice With a Central Catheter

Protective Effects of Heat Shock Protein70 Induced by Geranylgeranylacetone in Atrophic Gastritis in Rats

Effects of Acupuncture on Gastrointestinal Function and Gastrointestinal Hormone in Elderly Patients with Severe Pneumonia

[Effect of Early Enriched Parenteral Alanyl-Glutamine on Heat Shock Protein 70 (HSP70) Expression in Critical Patients].

The Effect of Glutamine in Strengthening Enteral Nutrition on ICU Patients in the Oxidative Stress State

Effect of L-ornithine L-aspartate Granules in Treating Chronic Liver Disease in Patients with High-Level Serum Gamma-Glutamyltransferase

Nutritional effects of glutamine-enriched parenteral nutrition in critical patients

A Short Term Study of Nutritional Effect of Intraperitoneal Amino Acid in CAPD Patients

Early enteral nutrition supplemented with glutamine on the clinical outcomes of patients after total gastrectomy

Effect of enteral nutrition support on patients with edematous pancreatitis

Enteral Nutrition Before Bowel Preparation Improves the Safety of Colonoscopy in the Elderly